LC-MS RNA Capping Analysis Without Radiolabels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for characterizing the 5' cap of mRNA are limited by the need for radiolabels and are not suitable for high-throughput analysis, particularly in the context of therapeutic mRNA development, where rapid and accurate characterization of in vitro transcribed mRNA is required.
Innovation Solution
A radiolabel-free method using nonradiolabeled tagged probes and liquid chromatography coupled with mass spectrometry (LC-MS) for identifying and quantifying the 5' end cap of mRNA, allowing for the determination of capping efficiency and orientation without the need for radiolabels, utilizing enzymes like RNAse H and 5' RNA pyrophosphohydrolase (RppH) for cleavage and analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If radiolabeled detection methods are used for 5' cap characterization, then measurement sensitivity is improved, but safety hazards and regulatory complexity increase due to radiolabel requirements
Solution Approach 1:
The patent replaces expensive and hazardous radiolabeled compounds with inexpensive, non-radioactive alternative labels such as fluorescent dyes, biotin, or mass-tagged moieties. These alternative labels provide sufficient detection sensitivity without the safety hazards of radiation, allowing for disposable, safer assay systems that can be easily handled and disposed of without special radiological precautions
Solution Approach 2:
The patent substitutes the radioactive detection mechanism with non-radioactive detection systems such as fluorescence detection, chemiluminescence, or mass spectrometry. This replacement eliminates the harmful radiation while maintaining or improving measurement precision through highly sensitive optical or mass-based detection methods
2Measurement precision
If enzymatic digestion followed by PAGE or HPLC with radiolabel detection is used, then 5' cap characterization accuracy is improved, but processing throughput is reduced
Solution Approach 1:
The patent segments the complex analytical process into modular steps: (1) enzymatic cleavage to release 5' caps, (2) affinity capture of cleaved products using solid support, and (3) parallel detection of multiple samples. This segmentation allows for streamlined processing and potential automation, improving throughput while maintaining characterization accuracy
Solution Approach 2:
The patent introduces solid support affinity capture as an intermediary step between enzymatic digestion and detection. This intermediary step concentrates the cleaved 5' cap products from multiple samples onto solid phases, enabling efficient washing and detection while facilitating high-throughput processing by allowing parallel handling of multiple samples
3Measurement precision
If sequence specific RNAse H probes are used to cleave 5' end sections, then capping efficiency measurement is improved, but the method remains limited to radiolabeled detection
Solution Approach 1:
The patent changes the detection parameter from radioactive signal to non-radioactive signals such as fluorescence intensity, chemiluminescence signal, or mass-to-charge ratio. This parameter change maintains the precision of capping efficiency measurement while eliminating the harmful radiolabel dependency, allowing the same RNAse H probe cleavage methodology to be used with safe alternative detection modes
4Measurement precision
If chromatographic resolution and retention time of standards are used for identification, then cap structure identification is achieved, but the method lacks sensitivity and throughput for therapeutic mRNA characterization
Solution Approach 1:
The patent uses solid support affinity capture as an intermediary to concentrate and pre-purify 5' cap structures from complex mRNA samples before analysis. This intermediary step enhances the sensitivity of subsequent detection methods and enables higher throughput by reducing sample complexity and allowing for automated processing and detection of multiple samples
Solution Approach 2:
The patent substitutes traditional chromatographic detection with more sensitive and higher-throughput detection methods such as mass spectrometry, fluorescence detection, or chemiluminescence. These replacement detection systems provide both the sensitivity needed for therapeutic mRNA characterization and the throughput capacity for rapid analysis of multiple samples
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate and high-resolution identification of 5' cap structures and capping efficiencies in mRNA samples, facilitating the analysis of therapeutic mRNA preparations with improved throughput and sensitivity, capable of detecting uncapped species and determining capping efficiencies across various mRNA lengths and modifications.
Implementation Method 1
treating the duplex polynucleotide with RNAse H, thus cleaving the 5' end of the target RNA
Implementation Method 2
isolating the duplex polynucleotide, using a surface coated substrate that is coated with a reagent that binds to the nonradiolabeled tagged probe
Implementation Method 3
analyzing the single-stranded fragment of the 5' end of the target RNA by liquid chromatography/mass spectrometry (LC-MS)
Implementation Method 4
analyzing the single-stranded fragment of the 5' end of the target RNA by liquid chromatography/mass spectrometry (LC-MS); identifying the 5' end cap
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Methods to qualitatively and quantitatively determine mRNA capping, and to determine 5' capping efficiency and 5' cap identity in RNA samples, all without the need for radiolabels, by using tagged probes that are complementary to the 5' end of target RNA and RNAse H to cleave the 5' end of RNA, then using LC-MS to determine the 5' RNA products.